Biotech Startups

Cornea Sense develops diagnostic technology for detecting systemic and ocular diseases through ocular hydration assessment. The company targets healthcare providers and patients globally to enable earlier disease diagnosis and preventive healthcare interventions.

1 investor

Cornerstone AI provides expert-guided AI software that organizes, standardizes, and harmonizes data across clinical trial datasets, labs, and EHRs to produce analysis-ready data for life science and pharma teams. Its platform offers automated ingestion, schema detection, standardization to industry ontologies, and human-in-the-loop review with full auditability.

1 investor

AeroRx is a clinical-stage biopharmaceutical company developing nebulized fixed-dose combination therapies (LABA/LAMA and triple LABA/LAMA/ICS) for moderate-to-severe COPD patients who are underserved by inhalers. Its pipeline targets high-risk respiratory patients, including older individuals and those with dexterity limitations who benefit from nebulized delivery.

1 investor

Corrixr Therapeutics is developing targeted genetic medicine for treatment-resistant cancers, with a focus on advancing its CXR101 therapeutic candidate through clinical development and translational research.

1 investor

Cortene is developing a patent-protected, peptide-based drug targeting the brain signaling believed to underlie acquired chronic diseases such as Parkinson's, Alzheimer's, dysautonomia, autoimmunity, and ME/CFS. The company operates in biotech, focusing on the root causes of brain-centric chronic conditions.

1 investor

Corventum is a biopharmaceutical company developing therapies that protect the heart from the toxic effects of cancer treatment, allowing patients to continue first-line oncology therapy. Its lead program, CVT-130, is a small molecule for the prevention of anthracycline cardiotoxicity, advancing into the clinic in 2026.

1 investor

Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

1 investor

Cosmica builds OrganAge™, a blood-based biomarker tool that scores biological aging across nine physiological systems, and an intervention engine that ranks foods, supplements, and activities by how they act on a person's aging-related genes. Aimed at individuals as well as clinics and platform partners, the company applies peer-reviewed aging research to longevity measurement and optimization.

1 investor

COSMIIC develops active implantable medical devices, including its Networked Neuroprosthesis (NNP) modular implant platform that stimulates muscles and records signals to restore function for people with disability and disease. It also provides resources to academic researchers to help translate implantable device concepts into systems tested in first-in-human studies.

1 investor

Cothera Bioscience is a clinical-stage biopharmaceutical company developing small molecule therapies targeting previously undruggable oncology targets through synthetic lethality, protein degradation, and immunotherapy mechanisms. The company's lead candidates are in Phase 2 trials for hematologic malignancies and high-grade gliomas with specific genetic mutations.

1 investor

Counsyl was a clinical genetic-screening company offering DNA carrier screening for family planning, prenatal screening, and inherited cancer risk tests, processed in its own CLIA-certified lab. Co-founded in 2007 with Balaji Srinivasan as CTO, it screened hundreds of thousands of patients before Myriad Genetics acquired it for $375 million in 2018.

1 investor

Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS. Its genomics tools serve scientists working in biomarker analysis, gene therapeutics, and clinical diagnostics.

1 investor

Couragene develops gene and biologic therapies using novel delivery platforms.

1 investor

CovalX provides mass spectrometry-based analytical services for biotherapeutic development, including epitope mapping, de novo sequencing, and monoclonal antibody characterization. It serves pharmaceutical and biotechnology companies across Europe and the United States, supporting drug discovery and development.

1 investor

Covirabio is a biotech startup developing point-of-care diagnostic test systems for detecting pathogens and monitoring immune responses, built on its VERB (Virus Entry Receptor Binding) platform that captures intact viral particles via host-pathogen interactions. Its portfolio covers SARS-CoV-2 virus detection, neutralizing-antibody immunity monitoring, and bacterial pathogen diagnosis, with assays integrated into microfluidic systems.

1 investor

1 investor

CpG Diagnostics develops epigenetic diagnostic technology to detect cancer through analysis of methylation changes, with an initial focus on ovarian cancer. The platform aims to enable earlier and more accurate diagnosis for gynecologic malignancies.

1 investor

CPTx is a genetic medicines company developing in vivo therapies using immune-silent, redosable single-stranded DNA technology. The company focuses on creating safe, durable treatments, with a lead program in CAR-T cell therapy and collaborations on novel genetic medicines.

1 investor

Crafton Biotechnology develops innovative mRNA-based medicines using proprietary RNA manufacturing, delivery, and synthesis technologies to create safer, scalable therapeutics for infectious diseases and rare conditions. The company focuses on overcoming key challenges in mRNA drug development including immunogenicity, manufacturing complexity, and delivery constraints.

1 investor

Crane Biosciences develops nanoparticles derived from red blood cells to carry nucleic acid therapeutics such as mRNA into the brain. The approach is intended to move these payloads across the blood-brain barrier without invasive administration. The company's focus is on treatments for neurological conditions.

1 investor

Creoptix, a Malvern Panalytical brand, develops bioanalytical instruments for molecular interaction analysis, including its WAVE biosensor system for real-time kinetics and affinity studies of molecules such as small molecules, peptides, and proteins. Its tools serve drug discovery and life sciences research for both industry and academia.

1 investor

Crestec Bio develops CTB211, a redox nanoparticle (polymer micelle carrying the TEMPO nitroxide radical scavenger) originally researched at the University of Tsukuba, designed to scavenge reactive oxygen species and protect neural cells. It is being developed as a therapeutic to reduce reperfusion injury after thrombectomy in ischemic stroke patients, with a focus on brain and organ disorders.

1 investor

1 investor

Cristcot is a pharmaceutical development and medical device company focused on drug formulations, device engineering, and clinical development. The company advances innovative science from concept through regulatory approval and commercialization.

1 investor